Akebia Therapeutics Stock News

ROCKVILLE, MD / ACCESSWIRE / June 22, 2020 / The American Kidney Fund (AKF) today announced a new corporate membership program open to institutional partners that support AKF's core mission of fi

Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the launch of AkebiaShares, a peer-to

Almost all the major components for manufacturing a smartphone are sourced from China, and are only assembled in India. That is the biggest challenge in becoming self-reliant on smartphone manufacturi

M&T Bank Corp increased its holdings in shares of Akebia Therapeutics Inc (NASDAQ:AKBA) by 48.5% during the 1st quarter, according to the company in its most recent filing with the Securities and Exch

The biggest life sciences deal this week involves a company that doesn’t discover or develop drugs, or even sell them. Yet its mark is found on

When it comes to smartphones, India is only an assembly hub right now, and we remain dependent on nations such as China for critical components.

Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose of bettering the lives of people impacted by kidney disease, today announced David A. Spellman is joining Akebi

Is (AKBA) Outperforming Other Medical Stocks This Year?

Introducing new model is not a priority due to the high costs involved, says expert
by RAHIMI YUNUS/ pic by MUHD AMIN NAHARUL CARMAKERS must put their new launches on the back burner amid uncertai

Through combined expertise, organizations will further improve the quality of life for patients living with chronic kidney disease in Arizona

Akebia Therapeutics (NASDAQ:AKBA) was downgraded by investment analysts at BidaskClub from a “buy” rating to a “hold” rating in a report issued on Saturday, BidAskClub reports. Several other r

Akebia Therapeutics Inc (NASDAQ:AKBA)’s share price shot up 6.3% during trading on Friday . The stock traded as high as $11.20 and last traded at $11.19, 1,402,030 shares were traded during trading.

Which stock wins in a battle between a COVID-19 testing leader and the top contract manufacturer for COVID-19 vaccines?

Akebia Therapeutics (AKBA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).